BD Seeks Potential Buyers for Life Sciences Business Division

Becton, Dickinson and Company (BDX) , popularly known as BD, is evaluating the divestment of its Life Sciences division as part of a broader strategic shift toward becoming a pure-play medtech company. According to a Financial Times report, BD has initiated discussions with several potential buyers, including Thermo Fisher Scientific, Danaher and a group of smaller diagnostics companies. This move follows BD’s February announcement that it would explore strategic alternatives for the unit, including a full ...